A Phase 4 interventional study of Cefazolin and Water for injection in Surgical Site Infection, sponsored by Monash University. Recruiting at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Monash University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing cefazolin in Surgical Wound Infection — 4 open to participants now, 5 under way, 2 of them phase 3. Cefazolin · Surgical Wound Infection.
Among the 18 studies testing cefazolin in Surgical Wound Infection, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2023, is one of 8 in phase 4, and was the 11th registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →4 of the 18 studies testing cefazolin in Surgical Wound Infection are open now, in 6 countries. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Helwan University
Ages 18+
Helwan University
Ages 18+
By country, each count listing its studies:
Cefazolin: first FDA approval 1973 (ANCEF). What it is approved for, and how studies give it, is on its page →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9,180 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 180 across the 18 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.
Monash University has 2 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing cefazolin in Surgical Wound Infection, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery
This trial will evaluate the clinical effectiveness, health-economic outcomes and microbiological impact of intraoperative (only) compared with intraoperative plus postoperative prophylaxis durations in patients undergoing cardiac surgery.
CALIPSO, a multicentre, adaptive, double-blind, three-arm, placebo-controlled, phase IV, noninferiority trial will examine the incidence proportion of SSI following cardiac surgery. Our three-intervention trial will compare:
Arm A Administration of prophylaxis in intraoperative period only Arm B Administration of prophylaxis in intraoperative plus for 24 hours postoperatively Arm C Administration of prophylaxis in intraoperative plus for 48 hours postoperatively
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Adult patients undergoing cardiac surgery involving a median sternotomy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
Drug: Water for injection
Cefazolin (2g) administered 8-hourly following the preoperative dose (time=0) for two doses then placebo 8-hourly for three doses (total of 5 postoperative doses of cefazolin/placebo)
Drug: Cefazolin · Drug: Water for injection
Cefazolin (2g) administered every 8-hours following the preoperative dose (time=0) for a total of five postoperative doses
Drug: Cefazolin
Intravenous administration of 2 g cefazolin
Intravenous administration of 10mL sterile water for injection
Incidence of surgical site infection
Surgical site infection according to CDC / NHSN definition
Time frame: 90 days from index surgery
Incidence of Clostridioides difficile infection
Clostridioides difficile infection according the CDC definitions
Time frame: 30 days from index surgery
Incidence of other health care association infections
Composite of all other HCAIs (pneumonia, blood stream infection and urinary tract infection)
Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery
Incidence of Antimicrobial hypersensitivity reactions
Immediate (\<48 hrs after exposure) or delayed (≥24 hrs after exposure) reaction to study drug
Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery
All-cause mortality rate
Death reported up to 180 days from index cardiac surgery due to any cause.
Time frame: 180 days from index surgery
Incidence of acute kidney injury
AKI will be defined according to the RIFLE criteria
Time frame: From date of randomization until the date of discharge from the acute healthcare facility or date of death from any cause, whichever came first, assessed up to 30 days from index surgery
Incidence of surgical site infections due to drug-resistant infections
Surgical site infections due to drug-resistant infections (defined as resistance to cefazolin)
Time frame: 90 days from index surgery
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.
Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 58 months is above that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefazolin
Monash University